Patient P-02299

Synthetic patientMETA-24 · Day 113 · 25–34 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

66%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 13 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 68 SC-12 recommended — Supportive Compound SC-12
Day 69 Patient accepted — Started SC-12 in the companion
Day 71 GI-04 recommended — GI Support Protocol GI-04
Day 72 Patient accepted — Started GI-04 in the companion
Day 75 No meaningful change — Supportive Compound SC-12
Day 80 GI symptom burden −36% vs expected — GI Support Protocol GI-04
Day 86 Tolerance state changed — Unstable → Improving
Day 92 ME-01 recommended — Monitoring Escalation ME-01
Day 93 Patient accepted — Started ME-01 in the companion
Day 96 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 13.

Primary contributors, last 14 days

Treatment adherence-18
GI instability+8
Inflammatory activity+6
Toxicity-4
Nutritional resilience+2

What helped?

Supportive Compound SC-12Day 68
Result: no meaningful change
GI Support Protocol GI-04Day 71
Result: symptom burden −36%
Monitoring Escalation ME-01Day 92
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Clinician Review CR-01

76%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

20 min

worsening · -5.2 vs previous 14 d

Sleep duration

Wearable

5.5 h

worsening · -0.3 vs previous 14 d

Energy level

Daily log

3.8/10

worsening · -0.7 vs previous 14 d

Steps

Wearable

1,866

worsening · -187 vs previous 14 d

GI burden

Companion

49.3/100

worsening · +9.5 vs previous 14 d

Adherence

Companion

62.9 %

worsening · -20.6 vs previous 14 d

Sleep quality

Wearable

23.3/100

worsening · -6.0 vs previous 14 d

Glucose, CGM daily mean

CGM

137 mg/dL

stable · +3.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 43 from the failing basin, 47 from restoration.

Would help

NP-02 Dietary Support Protocol
63% improved among 24 similar · onset 10 d · confidence 64%
DT-01 Dosing / Timing Recommendation
86% improved among 7 similar · onset 5 d · confidence 64%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 64%
More protein
GI -5.2 next day on high-intake days · n 15

Would not help

SC-12 Supportive Compound
already tried, no meaningful change
Keep fat low
GI +4.5 next day on high-intake days · n 28
Keep simple carbs low
GI +3.6 next day on high-intake days · n 19
Keep fibre low
GI +3.4 next day on high-intake days · n 18

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-5.2supporter · 95%
Dietary fat load
+4.5detractor · 95%
Simple carbohydrates
+3.6detractor · 80%
Insoluble fibre
+3.4detractor · 78%
Ultra-processed food
+3.4detractor · 91%
Alcohol
+1.2no signal · 20%
Histamine load
+1.1no signal · 22%
Caffeine
+0.3no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑65
- WearableResting HR 75 bpm
- Wearable1,866 steps/day
- WearableShort sleep window
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 51
Mucosal barrier integrity ↓30
- Daily logGI symptom score 49 and rising
- WearableSleep 5.5 h, below personal baseline

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2.8 · butyrate capacity 25/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 56 ms
Sleep: 6.0 h
Steps: 2,777
Resting HR: 72 bpm

Daily log: GI score 49, nutritional resilience 45, adherence 63.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02060	46%	S14	GI-04	improved	54
P-02460	43%	S18	GI-04	improved	59
P-02674	37%	S02	NP-02	improved	48
P-02176	36%	S14	GI-04	improved	52
P-02103	33%	S14	GI-04	improved	46
P-02115	33%	S14	GI-04	improved	75
P-02216	33%	S11	GI-04	improved	53
P-02298	33%	S14	GI-04	improved	65
P-02321	33%	S17	GI-04	improved	54
P-02410	33%	S01	GI-04	improved	55
P-02002	32%	S14	GI-04	improved	47
P-02328	32%	S14	GI-04	improved	42